/ALLR
ALLR Stock - Allarity Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.03+0.49%
+$0.01 (+0.49%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.23
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.13
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALLR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.02 – $1.04
TARGET (TP)$1.18
STOP LOSS$0.95
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.23
52W High$2.35
52W Low$0.61
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-27,241,000 | $-17,129,000 | $-34,463,000 | $-26,556,000 | $-8,319,000 |
| Net Income | $-24,515,000 | $-11,901,000 | $-16,058,000 | $-26,648,000 | $-6,602,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-15.79 | $-6153.26 | $-1856055.00 | $-3520104.00 | $-1698639.00 |
Company Overview
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$9
Average Target
↑ 773.8% Upside
Now
$9
Low
$9
Average
$9
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 28th 2025 | Ascendiant Capital Markets | Initiation | Buy | $9 |
Earnings History & Surprises
ALLRBeat Rate
42%
Last 12 quarters
Avg Surprise
-133796.7%
EPS vs Estimate
Beats / Misses
5/7
Last 12 quarters
Latest EPS
$-0.19
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
-37676.1%
$-664.86vs$-1.76
Q3 24
-1037.9%
$-3.30vs$-0.29
Q4 24
+9.5%
$-7.71vs$-8.52
Q2 25
+41.6%
$-4.73vs$-8.10
Q2 25
No data
Q3 25
+28.6%
$-0.15vs$-0.21
Q4 25
+17.4%
$-0.19vs$-0.23
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.23 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.23 | $-0.19 | +17.4% | ✓ BEAT |
Q3 2025 | Aug 15, 2025 | $-0.21 | $-0.15 | +28.6% | ✓ BEAT |
Q2 2025 | May 9, 2025 | — | $-0.25 | — | — |
Q2 2025 | Apr 4, 2025 | $-8.10 | $-4.73 | +41.6% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-8.52 | $-7.71 | +9.5% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-0.29 | $-3.30 | -1037.9% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-1.76 | $-664.86 | -37676.1% | ✗ MISS |
Q2 2024 | Apr 29, 2024 | — | $-175.51 | — | — |
Q4 2023 | Nov 14, 2023 | $-8.17 | $-1345.35 | -16367.0% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-11.19 | $-15783.78 | -140952.5% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-7.88 | $-106426.41 | -1350489.0% | ✗ MISS |
Q1 2023 | Mar 13, 2023 | $-0.42 | $-0.23 | +45.2% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-218400.19 | $-571200.50 | -161.5% | ✗ MISS |
Q4 2022 | Oct 7, 2022 | — | $-604800.56 | — | — |
Q2 2022 | May 27, 2022 | $-528.00 | $-312148.14 | -59019.0% | ✗ MISS |
Q2 2022 | May 17, 2022 | — | $-2143780.88 | — | — |
Q4 2021 | Nov 23, 2021 | — | $181151.96 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1388344.70 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-793744.14 | — | — |
Latest News
Allarity Therapeutics Files Prospectus To Offer Up To $50M In Various Securities
➖ NeutralBenzinga•Dec 3, 2025, 02:14 PM
Allarity Therapeutics Q3 EPS $(0.19) Beats $(0.21) Estimate
📈 PositiveBenzinga•Nov 14, 2025, 02:11 PM
Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.25
📈 PositiveBenzinga•Sep 26, 2025, 09:55 AM
Reported Earlier: Allarity Therapeutics Enters Into A Securities Purchase Agreement; Secures $2.5M
📈 PositiveBenzinga•Sep 23, 2025, 06:11 PM
Allarity Therapeutics Highlights Presentation Of Phase 2 Clinical Data For Stenoparib/2X-121, Showing Median Overall Survival Now Surpassed 25 Months
📈 PositiveBenzinga•Sep 22, 2025, 12:11 PM
Allarity Therapeutics shares are trading higher after the company announced that the FDA granted Fast Track designation to stenoparib.
📈 PositiveBenzinga•Aug 26, 2025, 12:04 PM
FDA Grants Allarity Therapeutics Granted Fast Track Designation For Stenoparib For Advanced Ovarian Cancer Treatment
📈 PositiveBenzinga•Aug 26, 2025, 12:04 PM
Frequently Asked Questions about ALLR
What is ALLR's current stock price?
Allarity Therapeutics, Inc. (ALLR) is currently trading at $1.03 per share. The stock has moved +0.49% today.
What is the analyst price target for ALLR?
No analyst price targets are currently available for this stock.
What sector is Allarity Therapeutics, Inc. in?
Allarity Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ALLR's market cap?
Allarity Therapeutics, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does ALLR pay dividends?
No, Allarity Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCTX
BriaCell Therapeutics Corp.
$8.95
Mkt Cap: $0.0B
CASI
CASI Pharmaceuticals, Inc.
$0.81
Mkt Cap: $0.0B
CING
Cingulate Inc.
$3.97
Mkt Cap: $0.0B
CLSD
Clearside Biomedical, Inc.
$1.00
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
KAPA
Kairos Pharma, Ltd.
$0.86
Mkt Cap: $0.0B
LEXX
Lexaria Bioscience Corp.
$0.58
Mkt Cap: $0.0B
LIXT
Lixte Biotechnology Holdings, Inc.
$4.32
Mkt Cap: $0.0B
PCSA
Processa Pharmaceuticals, Inc.
$3.78
Mkt Cap: $0.0B
Explore stocks similar to ALLR for comparison